SciVision Biotech Inc.

Taiwan Stock Exchange 1786.TW

SciVision Biotech Inc. Return on Equity (ROE) for the year ending December 31, 2023: 10.94%

SciVision Biotech Inc. Return on Equity (ROE) is 10.94% for the year ending December 31, 2023, a 16.61% change year over year. Return on equity measures profit against shareholder equity; higher ROE indicates superior profitability and value creation.

SciVision Biotech Inc. Return on Equity (ROE) for the year ending December 31, 2022 was 9.38%, a 33.69% change year over year.
SciVision Biotech Inc. Return on Equity (ROE) for the year ending December 31, 2021 was 7.02%, a -23.04% change year over year.
SciVision Biotech Inc. Return on Equity (ROE) for the year ending December 31, 2020 was 9.12%, a 2.77% change year over year.
SciVision Biotech Inc. Return on Equity (ROE) for the year ending December 31, 2019 was 8.87%, a 10.08% change year over year.

Key data

Date	Return on Equity (ROE)	Return on Capital Employed (ROCE)	Interest Coverage Ratio	Debt to Equity Ratio

Taiwan Stock Exchange: 1786.TW

SciVision Biotech Inc.

CEO	Tai Xian Han
IPO Date	March 12, 2013
Location	Taiwan
Headquarters	1, South 1st Road
Employees	64
Sector	Consumer Discretionary
Industries Cosmetics 3D Printing Composite Materials Dental Care Eyewear Luxury Goods Personal Care Plastics

Description

SciVision Biotech Inc. manufactures and sells hyaluronic acid products in Taiwan. It offers synovial fluid supplements, facial dermal implants, absorbable adhesion barriers, and intravesical instillation products. The company was founded in 2001 and is based in Kaohsiung, Taiwan.

Key trends

Past 5 years